Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · OCULAR THERAPEUTIX, INC (OCUL)

Ocular Therapeutix Q3 revenue falls to $12.9 million; net loss widens to $94.8 million

Negative Impact 3 of 5 earnings

Ocular Therapeutix reported third quarter 2026 results with total net revenue of $12.9 million, down from $14.5 million a year earlier, and a net loss of $94.8 million, or $(0.42) per share, versus a net loss of $69.4 million, or $(0.38) per share, in the prior-year quarter. Research and development expenses rose to $74.8 million from $52.4 million, and the company said it had $530.6 million in cash as of September 30, 2026, with runway expected into 2028.

Key points

  • Net revenue was $12.9 million for Q3 2026, compared with $14.5 million for Q3 2025.
  • Net loss was $(94.8) million, or $(0.42) per share, versus $(69.4) million, or $(0.38) per share, a year earlier.
  • R&D expenses were $74.8 million versus $52.4 million, reflecting faster HELIOS-3 and SOL-X enrollment and higher headcount.
  • Cash and cash equivalents were $530.6 million as of September 30, 2026; the company expects this to support operations into 2028.

The filing

CompanyOCULAR THERAPEUTIX, INC (OCUL)
Form8-K, current report
Filed with the SECNov 9, 2026, 7:08 AM ET
Accession number0001104659-26-124151

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:16 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.